Ann Rheum Dis 1999;58:281-287 ( May )

Extended reports

Prospective six year follow up of patients withdrawn from a randomised study comparing parenteral gold salt and methotrexate Oliver Sander, Gertraud Herborn, Elisabeth Bock, Rolf Rau

Department of Rheumatology, Ratingen, Germany

Correspondence to: Dr O Sander, Rheumatologie, Ev Fachkrankenhaus Ratingen, Rosenstr 2, 40882 Ratingen, Germany.

Accepted for publication 25 January 1999

OBJECTIVETo confirm the impression of a better outcome of patients withdrawn from parenteral gold salt therapy compared with those withdrawn from methotrexate.
METHODSPatients with early, active, and erosive RA were randomised for a double blind trial to receive either weekly 15 mg intramuscular methotrexate or 50 mg goldsodiumthiomalate. If the drug had to be withdrawn because of side effects treatment was continued with the other drug in still active disease. Patients with insufficient response were treated with a combination of both drugs. All patients were followed up by an extended clinical and radiographic evaluation.
RESULTS64 patients each were allocated to methotrexate and gold treatment. After 72 months a complete record was available for 88% of patients. Within the first 36 months 38 patients withdrew from gold treatment (95% because of side effects) and 23 patients withdrew from methotrexate (57% because of side effects). A significant 40% to 70% improvement of all parameters (erythrocyte sedimentation rate, C reactive protein, swollen and tender joints, radiological progression) compared with baseline was observed in patients completing their randomised treatment with gold or methotrexate. The same improvement over three years was seen in patients who withdrew from gold treatment, while patients withdrawing from methotrexate experienced a deterioration of their disease.
CONCLUSIONWithdrawals represent the majority of patients in long term drug trials. Patients with early RA stopping gold because of side effects show almost the same sustained improvement as patients continuing gold or methotrexate. Patients withdrawn from methotrexate experience a reactivation of their disease.

---

© 1999 by Annals of the Rheumatic Diseases
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Salliot, C, van der Heijde, D (2009). Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 68: 1100-1104 [Abstract] [Full Text]  
• Pucino, F. Jr., Harbus, P. T., Goldbach-Mansky, R. (2006). Use of biologics in rheumatoid arthritis: Where are we going?. Am J Health Syst Pharm 63: S19-S41 [Abstract] [Full Text]  
• Kinder, A. J., Hassell, A. B., Brand, J., Brownfield, A., Grove, M., Shadforth, M. F. (2005). The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford) 44: 61-66 [Abstract] [Full Text]  
• Landewe, R, van der Heijde, D (2002). Follow up studies in rheumatoid arthritis. Ann Rheum Dis 61: 479-481 [Full Text]  
• Rau, R., Herborn, G., Menninger, H., Sangha, O. (2002). Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients. Rheumatology (Oxford) 41: 196-204 [Abstract] [Full Text]  
• Hamilton, J, McInnes, I B, Thomson, E A, Porter, D, Hunter, J A, Madhok, R, Capell, H A (2001). Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area. Ann Rheum Dis 60: 566-572 [Abstract] [Full Text]  
• Maetzel, A., Wong, A., Strand, V., Tugwell, P., Wells, G., Bombardier, C. (2000). Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 39: 975-981 [Abstract] [Full Text]